Literature DB >> 19195711

Mycobacterium xenopi pulmonary disease - epidemiology and clinical features in non-immunocompromised patients.

Ante Marusić1, Vera Katalinić-Janković, Sanja Popović-Grle, Mateja Janković, Ivica Mazuranić, Igor Puljić, Helga Sertić Milić.   

Abstract

OBJECTIVES: The genus Mycobacterium has more than 120 well-characterized species. Although the incidence of tuberculosis has decreased over the studied period, other, non-tuberculous mycobacteria (NTM) are isolated more often. Since, Mycobacterium xenopi is the most frequent NTM isolate in Croatia we studied its epidemiology and clinical relevance.
METHODS: We performed a retrospective study over a 25-year period determining epidemiology, radiological findings and clinical importance of M. xenopi infection, obtaining data from archives in health care institutions from all over the country.
RESULTS: We detected 40 patients with a positive isolate of M. xenopi. Twenty-four patients met American Thoracic Society criteria for pulmonary disease. Eighteen (90%) of treated patients were male, on average 61.7 years old. Nineteen (95%) patients lived in towns. Most of them had comorbid disease, 18 (90%), with chronic obstructive pulmonary disease (COPD) being the most frequent, found in 11 (55%) patients. All patients were immunocompetent. We found COPD as the most frequent comorbid disease in the group of patients with worse treatment response (n=8; 80%), while in patients with good treatment response COPD was less frequent (n=3; 30%). Differences in the proportions of patients with COPD were significant (p=0.037).
CONCLUSION: In patients with M. xenopi pulmonary infection, COPD is a predisposing condition, and as a comorbid disease, is an important prognostic factor for treatment response.

Entities:  

Mesh:

Year:  2009        PMID: 19195711     DOI: 10.1016/j.jinf.2009.01.001

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  11 in total

Review 1.  Nontuberculous mycobacteria and the lung: from suspicion to treatment.

Authors:  Emmet E McGrath; Zoe Blades; Josie McCabe; Hannah Jarry; Paul B Anderson
Journal:  Lung       Date:  2010-04-09       Impact factor: 2.584

2.  Nontuberculous mycobacterial lung infections in Ontario, Canada: clinical and microbiological characteristics.

Authors:  Theodore K Marras; Mauli Mehta; Pamela Chedore; Kevin May; Mohammed Al Houqani; Frances Jamieson
Journal:  Lung       Date:  2010-04-11       Impact factor: 2.584

3.  Non-tuberculous Mycobacteria isolated from Pulmonary samples in sub-Saharan Africa - A Systematic Review and Meta Analyses.

Authors:  Catherine Okoi; Suzanne T B Anderson; Martin Antonio; Sarah N Mulwa; Florian Gehre; Ifedayo M O Adetifa
Journal:  Sci Rep       Date:  2017-09-20       Impact factor: 4.379

Review 4.  Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review.

Authors:  D Rebecca Prevots; Theodore K Marras
Journal:  Clin Chest Med       Date:  2014-11-06       Impact factor: 2.878

5.  Multilocus sequence typing of Mycobacterium xenopi.

Authors:  David C Alexander; Theodore K Marras; Jennifer H Ma; Samia Mirza; Daniel Liu; Julianne V Kus; Hafid Soualhine; Vincent Escuyer; David Warshauer; Sarah K Brode; David J Farrell; Frances B Jamieson
Journal:  J Clin Microbiol       Date:  2014-09-10       Impact factor: 5.948

6.  Species-Specific Risk Factors, Treatment Decisions, and Clinical Outcomes for Laboratory Isolates of Less Common Nontuberculous Mycobacteria in Washington State.

Authors:  Emily S Ford; David J Horne; Javeed A Shah; Carolyn K Wallis; Ferric C Fang; Thomas R Hawn
Journal:  Ann Am Thorac Soc       Date:  2017-07

7.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

8.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

9.  Mycobacterium xenopi systemic infection in a domestic fiery-shouldered conure bird (Pyrrhura egregia).

Authors:  Guillaume St-Jean; Carl A Gagnon; Hafid Soualhine; Manon Tremblay; Andrée-Anne Beaulieu; Doris Sylvestre
Journal:  JMM Case Rep       Date:  2018-07-04

10.  Evidence of mycobacterial disease in COPD patients with lung volume reduction surgery; the importance of histological assessment of specimens: a cohort study.

Authors:  Anjali Char; Nick S Hopkinson; David M Hansell; Andrew G Nicholson; Emily C Shaw; Samuel J Clark; Philip Sedgwick; Robert Wilson; Simon Jordan; Michael R Loebinger
Journal:  BMC Pulm Med       Date:  2014-08-02       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.